Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers

Authors:
Susan M. DomchekFrom the Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Search for other papers by Susan M. Domchek in
Current site
Google Scholar
PubMedClose
 MD
,
Jill E. StopferFrom the Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Search for other papers by Jill E. Stopfer in
Current site
Google Scholar
PubMedClose
 MS, CGC
, and
Timothy R. RebbeckFrom the Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
From the Abramson Cancer Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, and Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Search for other papers by Timothy R. Rebbeck in
Current site
Google Scholar
PubMedClose
 PhD
View More View Less
Volume/Issue:
Volume 4: Issue 2
Online Publication Date:
Feb 2006
DOI:
https://doi.org/10.6004/jnccn.2006.0017
Full access

Bilateral risk-reducing oophorectomy (BRRO) is widely used for cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations. BRRO significantly reduces breast cancer risk by approximately 50% and ovarian cancer risk by 85% to 95%, but it may be accompanied by menopausal symptoms, impaired quality of life, and accelerated bone loss. Therefore, decisions regarding the timing of BRRO, the risks and benefits of a simultaneous hysterectomy, and the use of hormone replacement therapy (HRT) must be made in concert with the patient and individualized to their circumstances. However, recent data demonstrate that HRT after BRRO in unaffected premenopausal women does not negate the breast cancer risk reduction that BRRO provides. This article reviews the studies regarding BRRO in BRCA1/2 mutation carriers, with particular focus on the use of HRT.

Correspondence to: Susan M. Domchek, MD, Abramson Cancer Center, University of Pennsylvania, 14 Penn Tower, Philadelphia, PA 19104. E-mail: susan.domchek@uphs.upenn.edu
  • Collapse
  • Expand
  • 1.

    Rebbeck TR, Lynch HT, Neuhausen SL et al.. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–1622.

  • 2.

    Kauff ND, Satagopan JM, Robson ME et al.. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–1615.

    • Search Google Scholar
    • Export Citation
  • 3.

    Rutter JL, Wacholder S, Chetrit A et al.. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003;95:1072–1078.

    • Search Google Scholar
    • Export Citation
  • 4.

    Rebbeck TR, Levin AM, Eisen A et al.. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475–1479.

    • Search Google Scholar
    • Export Citation
  • 5.

    Struewing JP, Watson P, Easton DF et al.. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 1995;17:33–35.

    • Search Google Scholar
    • Export Citation
  • 6.

    White CD. Papillary intraperitoneal neoplasia resembling ovarian carcinoma after removal of benign ovaries. W V Med J 1993;89:282–283.

    • Search Google Scholar
    • Export Citation
  • 7.

    Kemp G, Hsiu J, Andrews M. Papillary peritoneal carcinomatosis after prophylactic oophorectomy. Gynecol Oncol 1992;47:395–397.

  • 8.

    Chen K, Schooley J, Flam M. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 1985;66:93s–94s.

    • Search Google Scholar
    • Export Citation
  • 9.

    Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751–2755.

    • Search Google Scholar
    • Export Citation
  • 10.

    Tobacman JK, Greene MH, Tucker MA et al.. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovariancancer-prone families. Lancet 1982;2:795–797.

    • Search Google Scholar
    • Export Citation
  • 11.

    Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma. Am J Obstet Gynecol 1959;77:197–200.

  • 12.

    Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000;18:1980–1995.

    • Search Google Scholar
    • Export Citation
  • 13.

    Fromm G, Gershenson DM, Silva EG. Papillary Serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89–95.

  • 14.

    Zhou J, Iwasa Y, Knoishi I et al.. Papillary Serous carcinoma of the peritoneum in women. Cancer 1995;76:429–436.

  • 15.

    Casey MJ, Synder C, Bewtra C et al.. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005;97:457–467.

    • Search Google Scholar
    • Export Citation
  • 16.

    Salazar H, Godwin AK, Daly MB et al.. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810–1820.

    • Search Google Scholar
    • Export Citation
  • 17.

    Lu KH, Garber JE, Cramer DW et al.. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728–2732.

    • Search Google Scholar
    • Export Citation
  • 18.

    Powell CB, Kenley E, Chen LM et al.. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005;23:127–132.

    • Search Google Scholar
    • Export Citation
  • 19.

    McEwen AR, McConnell DT, Kenwright DN et al.. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecol Oncol 2004;92:992–994.

    • Search Google Scholar
    • Export Citation
  • 20.

    Carcangiu ML, Radice P, Manoukian S et al.. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004;23:35–40.

    • Search Google Scholar
    • Export Citation
  • 21.

    Colgan TJ, Murphy J, Cole DE et al.. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283–1289.

    • Search Google Scholar
    • Export Citation
  • 22.

    Aziz S, Kuperstein G, Rosen B et al.. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341–345.

  • 23.

    Brose MS, Rebbeck TR, Calzone KA et al.. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365–1372.

    • Search Google Scholar
    • Export Citation
  • 24.

    Colgan TJ, Boerner SL, Murphy J et al.. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002;85:397–403.

    • Search Google Scholar
    • Export Citation
  • 25.

    Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy—effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14:283–293.

    • Search Google Scholar
    • Export Citation
  • 26.

    Pouilles JM, Tremollieres F, Bonneu M, Ribot C. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 1994;9:311–315.

  • 27.

    Frank TS, Manley SA, Olopade OI et al.. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998;16:2417–2425.

    • Search Google Scholar
    • Export Citation
  • 28.

    Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers [letter]. Lancet 1998;352:1359–1360.

    • Search Google Scholar
    • Export Citation
  • 29.

    Levy-Lahad E, Catane R, Eisenberg S et al.. Founder/BRCA1/and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059–1067.

    • Search Google Scholar
    • Export Citation
  • 30.

    Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465–1471. Erratum appears in N Engl J Med 1997;337:434.

    • Search Google Scholar
    • Export Citation
  • 31.

    NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995;273:491–497.

    • Search Google Scholar
    • Export Citation
  • 32.

    Rossouw JE, Anderson GL, Prentice RL et al.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    • Search Google Scholar
    • Export Citation
  • 33.

    Anderson GL, Limacher M, Assaf AR et al.. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.

    • Search Google Scholar
    • Export Citation
  • 34.

    Kelly JP, Kaufman DW, Rosenberg L et al.. Use of postmenopausal hormone therapy since the Women's Health Initiative findings. Pharmacoepidemiol Drug Saf 2005;5:5.

    • Search Google Scholar
    • Export Citation
  • 35.

    Rebbeck TR, Friebel T, Wagner TM et al.. Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2005;23:7804–7810.

    • Search Google Scholar
    • Export Citation
  • 36.

    Armstrong K, Schwartz JS, Randall T et al.. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045–1054.

    • Search Google Scholar
    • Export Citation
  • 37.

    Russell J. Laparoscopic oophorectomy. Curr Opin Obstetr Gynecol 1995;7:295–298.

  • 38.

    Escobedo L, Peterson H, Grubb G et al.. Case-fatality rates for tubal sterilization in U.S. hospitals, 1979 to 1980. Am J Obstet Gynecol 1989;160:147–150.

    • Search Google Scholar
    • Export Citation
  • 39.

    Menczer J, Dan U, Oelsner G. Laparoscopic prophylactic oophorectomy in women belonging to ovarian cancer prone familes. Advantages and shortcomings. Eur J Gynaecol Oncol 1994;15:105–107.

    • Search Google Scholar
    • Export Citation
  • 40.

    Menczer J, Ben-Baruch G. Familial ovarian cancer in Israeli Jewish women. Obstet Gynecol 1991;77:276–277.

  • 41.

    Grady D, Gebretsadik T, Kerlikowske K et al.. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304–313.

    • Search Google Scholar
    • Export Citation
  • 42.

    Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–427.

  • 43.

    Lavie O, Hornreich G, Ben-Arie A et al.. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004;92:521–524.

    • Search Google Scholar
    • Export Citation
  • 44.

    Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358–1365.

  • 45.

    Narod SA, Brunet JS, Ghadirian P et al.. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876–1881.

    • Search Google Scholar
    • Export Citation
  • 46.

    Fisher B, Costantino JP, Wickerham DL et al.. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–1388.

    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2006 by the National Comprehensive Cancer Network
Page Numbers:
6
Article Category:
Research Article
Received:
27 Sep 2005
Accepted:
21 Oct 2005
Print Publication Date:
01 Feb 2006
Online Publication Date:
Feb 2006
Keywords:
BRCA1; BRCA2; oophorectomy; hormone replacement therapy; estrogen; hysterectomy; breast cancer; ovarian cancer
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1245 100 10
PDF Downloads 1012 65 11
EPUB Downloads 0 0 0